Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGENCY: Obinutuzumab in Lupus Nephritis
NCT04221477Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2020
- Primary completion
- Aug 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) comparing Obinutuzumab with Placebo (2 arms). Primary endpoint: Complete Renal Response at 76 weeks. Started Aug 2020; status: active, not recruiting.
02
Drugs
obinutuzumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT04221477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221477.